Ivana Šarac
Jasmina Debeljak Martačić
Kathryn Hart
Jelena Milešević- 1Centre of Research Excellence in Nutrition and Metabolism, Group for Nutrition and Metabolism, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia
- 2Discipline of Nutrition, Exercise, Chronobiology and Sleep, School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom
Editorial on the Research Topic
The role of vitamin D in metabolic and cardiovascular health, volume II
Over the past two decades, few nutrients have attracted as much scientific and public attention as vitamin D (VitD). Originally recognized almost exclusively for its pivotal role in calcium homeostasis and bone metabolism, VitD has emerged as a pleiotropic secosteroid hormone with widespread physiological functions. Advances in molecular biology, endocrinology, and immunology have profoundly expanded our understanding of VitD signaling pathways, revealing its importance in numerous tissues far beyond the skeletal system (1, 2). As a result, VitD deficiency has been increasingly implicated in a wide range of chronic non-communicable diseases, particularly those linked to metabolic health, immune function, and cardiovascular physiology (2–5).
Correspondingly, global interest in VitD has grown exponentially. This surge reflects both an increased prevalence of VitD deficiency worldwide (6–8) and the expanding body of evidence linking inadequate VitD status to obesity, insulin resistance, type 2 diabetes, metabolic syndrome (MetS), dyslipidemia, non-alcoholic fatty liver disease (NAFLD), hypertension, atherosclerosis, and cardiovascular morbidity and mortality (5, 9–15). Parallel interest emerged during the COVID-19 pandemic, when VitD deficiency was proposed as a contributing factor to increased disease severity and poor outcomes, particularly in individuals with pre-existing metabolic and cardiovascular dysfunction (16–18).
However, despite widespread enthusiasm and significant scientific advancements, controversies persist, and findings across mechanistic, epidemiological, and interventional studies remain inconsistent (3). Many of the biological pathways through which VitD influences metabolic and cardiovascular health remain poorly defined, and “cause–and–effect” relationships are often uncertain (3). Moreover, the relationship between VitD deficiency and cardiometabolic disorders appears to be bidirectional and influenced by a multitude of confounding factors, including adiposity, lifestyle behaviors, genetic background, chronic inflammation, environmental exposures, and comorbidities (3). While findings from observational studies cannot reliably establish causality and Mendelian randomization studies provide mixed results, the available RCTs vary widely in design, VitD dose, baseline deficiency status, endpoints, and follow-up duration (2, 13–15, 19). Additionally, different subgroups—based on genetics, epigenetics, ethnicity, age, adiposity, inflammation levels, microbiota composition, and comorbidities—might respond differently to VitD supplementation (20, 21).
In light of the complexities and significant scientific gaps related to the causal pathways connecting VitD to metabolic and cardiovascular health, in 2022, we established the Frontiers Research Topic titled “The Role of Vitamin D in Metabolic and Cardiovascular Health.” This Research Topic aimed to address these gaps by presenting studies that focused on: (1) the pathophysiological mechanisms underlying the bidirectional relationships between VitD and metabolic or cardiovascular disorders; (2) epidemiological evidence across various population subgroups; (3) individual responses to VitD supplementation and its potential as an adjunctive therapy for individuals with cardiometabolic diseases; and (4) the role of VitD as an immunomodulator (3). Due to the success of this Topic and the 13 high-quality articles associated with it, in 2024, we launched the Topic extension titled “The Role of Vitamin D in Metabolic and Cardiovascular Health - Volume II.”
The present volume builds on the first volume's findings and presents nine new contributions that deepen our understanding of VitD's multifaceted involvement in cardiometabolic, vascular, and reproductive health. The nine articles in this Research Topic reveal new layers of nuance—including stratified population risk, new mechanistic insights, new implications, and translational boundaries.
Several studies highlight the further cardiometabolic implications of VitD deficiency. Hung et al. extended the cardiometabolic risk profile by showing that VitD deficiency is associated with increased risk for venous thromboembolism (deep vein thrombosis and pulmonary embolism), in a dose-response fashion, pointing to potential effects on endothelial or coagulation pathways, as well as higher mortality and intensive care unit (ICU) admission. Li et al. demonstrated that hypertensive individuals with low VitD levels exhibit altered heart rate variability, renin-angiotensin-aldosterone system (RAAS) activity, and a greater need for coronary revascularization, implying impaired autonomic and endocrine regulation and higher cardiovascular burden.
Other studies collectively reinforce the idea that VitD's health effects are not isolated but interact with other lifestyle and biological factors. Cai et al. showed that the relationship between VitD, lipid status, inflammation, and mortality is highly modulated by glycemic status and gender, suggesting that genetic and metabolic background modify VitD's physiological effects. Wang et al. found that concurrent VitD deficiency and sleep disorders markedly increase cardiovascular mortality, indicating possible synergistic effects.
Another group of studies emphasizes VitD's role in disease progression and clinical prognosis. Lin et al. demonstrated that chronic kidney disease (CKD) patients with low VitD experience more major adverse kidney events (MAKE), higher mortality and hospitalization rates, underscoring potential renoprotective effects of VitD. Fu et al. found that among individuals with sarcopenia, VitD has a non-linear association with all-cause and cardiovascular mortality, suggesting threshold levels that may lower mortality. Zheng et al.'s meta-analysis in critically ill patients indicates that VitD supplementation may improve some clinical outcomes, particularly in ventilated patients, including short-term mortality, duration of ICU hospitalization, and need for mechanical ventilation. Nevertheless, the evidence remains inconsistent and of low level of evidence, highlighting the need for additional high-quality trials.
Two articles focus specifically on endocrine-metabolic disorders affecting women, and indicate the growing evidence of VitD's role in both metabolic and reproductive health in women. Song's opinion article argues for a plausible link between VitD deficiency and polycystic ovary syndrome (PCOS), emphasizing its role in reproductive and metabolic dysregulation, and advocates for further studies to elucidate the precise mechanism and therapeutic potential. Zhang et al.'s mini-review similarly identifies VitD insufficiency as a risk factor for gestational diabetes mellitus (GDM), with possible mechanisms involving insulin sensitivity, β-cell function, and inflammation, and calls for more high-quality intervention trials.
Taken together, the nine studies collectively depict VitD as a versatile physiological modulator that influences cardiovascular, metabolic, renal, endocrine, reproductive, and immune pathways. Across populations—including hypertensive individuals, CKD patients, sarcopenic adults, critically ill patients, infertile and pregnant women, and those at thrombotic risk—low VitD consistently associates with adverse outcomes. Importantly, several studies demonstrate that VitD's effects are shaped by contextual modifiers such as glycemic status, gender, sleep quality, and comorbid disease, highlighting the need for targeted, individualized supplementation strategies. However, more well-designed studies are needed to address the numerous gaps identified in the research presented.
Author contributions
IŠ: Writing – original draft, Writing – review & editing, Conceptualization. JD-M: Writing – original draft, Writing – review & editing. KH: Writing – original draft, Writing – review & editing. JM: Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was financially supported for IŠ, JD-M, and JM by the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia, Contract Number: 451-03-136/2025-03/200015.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors IŠ, JD-M, and JM declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Voiculescu VM, Nelson Twakor A, Jerpelea N, Pantea Stoian A. Vitamin D: beyond traditional roles—insights into its biochemical pathways and physiological impacts. Nutrients. (2025) 17:803. doi: 10.3390/nu17050803
2. Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, et al. Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev. (2019) 40:1109–51. doi: 10.1210/er.2018-00126
3. Šarac I, Djekić-Ivanković M, Debeljak-Martačić J. Editorial: The role of vitamin D in metabolic and cardiovascular health. Front Nutr. (2023) 10:1193758. doi: 10.3389/fnut.2023.1193758
4. Šarac I. The influence of metabolic syndrome on reproductive health: the impact of low vitamin D. In: Reference Module in Food Science. Amsterdam: Elsevier (2019) 1–10. doi: 10.1016/B978-0-08-100596-5.22524-9
5. Renke G, Starling-Soares B, Baesso T, Petronio R, Aguiar D, Paes R. Effects of vitamin D on cardiovascular risk and oxidative stress. Nutrients (2023) 15:769. doi: 10.3390/nu15030769
6. Wilson LR, Tripkovic L, Hart KH, Lanham-New SA. Vitamin D deficiency as a public health issue: using vitamin D2 or vitamin D3 in future fortification strategies. Proc Nutr Soc. (2017) 76:392–9. doi: 10.1017/S0029665117000349
7. Milešević J, Samaniego L, Kiely M, Glibetić M, Roe M, Finglas P. Specialized food composition dataset for vitamin D content in foods based on European standards: application to dietary intake assessment. Food Chem. (2018) 240:544–9. doi: 10.1016/j.foodchem.2017.07.135
8. Vearing RM, Hart KH, Charlton K, Probst Y, Blackbourn D, Ahmadi K, et al. Vitamin D status of British African-Caribbean residents: analysis of the UK Biobank cohort. Proc Nutr Soc. (2022) 81:E36. doi: 10.1017/S0029665122000362
9. Šarac I, Jovanović J, Zec M, Pavlović Z, Debeljak-Martačić J, Zeković M, et al. Vitamin D status and its correlation with anthropometric and biochemical indicators of cardiometabolic risk in serbian underground coal miners in 2016. Front Nutr. (2021) 8:689214. doi: 10.3389/fnut.2021.689214
10. Carbone F, Liberale L, Libby P, Montecucco F. Vitamin D in atherosclerosis and cardiovascular events. Eur Heart J. (2023) 44:2078–94. doi: 10.1093/eurheartj/ehad165
11. Jespersen FE, Grimm D, Krüger M, Wehland M. Current knowledge of the impact of vitamin D in coronary artery disease. Int J Mol Sci (2025) 26:5002. doi: 10.3390/ijms26115002
12. Koga GKC, Maeda SS, Lazaretti-Castro M. Rapid and dose-dependent increase of 25(OH)D levels after calcifediol supplementation in a woman with obesity, chronic liver disease, and osteoporosis. Arch Endocrinol Metab. (2025) 69:e240428. doi: 10.20945/2359-4292-2024-0428
13. Bjelakovic M, Nikolova D, Bjelakovic G, Gluud C. Vitamin D supplementation for chronic liver diseases in adults. Cochrane database Syst Rev. (2021) 8:CD011564. doi: 10.1002/14651858.CD011564.pub3
14. Musazadeh V, Zarezadeh M, Ghalichi F, Kalajahi FH, Ghoreishi Z. Vitamin D supplementation positively affects anthropometric indices: evidence obtained from an umbrella meta-analysis. Front Nutr. (2022) 9:980749. doi: 10.3389/fnut.2022.980749
15. Argano C, Mirarchi L, Amodeo S, Orlando V, Torres A, Corrao S. The role of vitamin D and its molecular bases in insulin resistance, diabetes, metabolic syndrome, and cardiovascular disease: state of the art. Int J Mol Sci. (2023) 24:15485. doi: 10.20944/preprints202309.0595.v1
16. Sabit H, Abdel-Ghany S, Abdallah MS, Abul-Maaty O, Khoder AI, Shoman NA, et al. Vitamin D: a key player in COVID-19 immunity and lessons from the pandemic to combat immune-evasive variants. Inflammopharmacology. (2024) 32:3631–52. doi: 10.1007/s10787-024-01578-w
17. Caliman-Sturdza OA, Gheorghita RE, Soldanescu I. Vitamin D and COVID-19: clinical evidence and immunological insights. Life. (2025) 15:733. doi: 10.3390/life15050733
18. Rizzi M, Sainaghi PP. Vitamin D: a nutraceutical supplement at the crossroad between respiratory infections and COVID-19. Int J Mol Sci. (2025) 26:2550. doi: 10.3390/ijms26062550
19. Pieńkowska A, Janicka J, Duda M, Dzwonnik K, Lip K, Medza A, et al. Controversial impact of vitamin D supplementation on reducing insulin resistance and prevention of type 2 diabetes in patients with prediabetes: a systematic review. Nutrients. (2023) 15:983. doi: 10.3390/nu15040983
20. Bilezikian JP, Formenti AM, Adler RA, Binkley N, Bouillon R, Lazaretti-Castro M, et al. Vitamin D: dosing, levels, form, and route of administration: does one approach fit all? Rev Endocr Metab Disord. (2021) 22:1201–18. doi: 10.1007/s11154-021-09693-7
Keywords: chronic kidney disease (CKD), critically ill, gestational diabetes, hypertension, mortality, polycystic ovary syndrome (PCOS), thromboembolism, vitamin D
Citation: Šarac I, Debeljak Martačić J, Hart K and Milešević J (2026) Editorial: The role of vitamin D in metabolic and cardiovascular health, volume II. Front. Nutr. 12:1759053. doi: 10.3389/fnut.2025.1759053
Received: 02 December 2025; Accepted: 08 December 2025;
Published: 07 January 2026.
Edited and reviewed by: Paula Ravasco, Catholic University of Portugal, Portugal
Copyright © 2026 Šarac, Debeljak Martačić, Hart and Milešević. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ivana Šarac, aXZhbmEuc2FyYWNAaW1pLmJnLmFjLnJz